Omega Therapeutics details Phase 2 liver trial plans, shares trade on Nasdaq

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-25, 21:21.

Omega Therapeutics (US68218K1025) is a clinical-stage biotechnology company developing epigenomic therapies and its stock trades on the Nasdaq in New York. The company is currently preparing for a Phase 2 clinical trial of its lead candidate OTX-2002 in hepatocellular carcinoma, supported by recent clinical updates published on its investor relations website and in regulatory filings.

OTX-2002 moves toward Phase 2

Omega Therapeutics reports that OTX-2002 is designed as an mRNA-encoded epigenomic controller targeting the c-Myc oncogene in liver cancer, aiming to modulate gene expression without permanently altering DNA. The company describes OTX-2002 as its most advanced clinical candidate in hepatocellular carcinoma in its recent corporate materials. Company investor information on the OMEGA platform

According to Omega Therapeutics, the planned Phase 2 program in hepatocellular carcinoma builds on initial safety and pharmacodynamic data from earlier-stage trials in patients with advanced liver tumors. The company indicates that further study design details, including dosing cohorts and primary endpoints, are being developed in preparation for discussions with regulators such as the U.S. Food and Drug Administration.

Clinical-stage pipeline beyond liver cancer

Beyond OTX-2002, Omega Therapeutics highlights additional preclinical and early clinical programs that apply its OMEGA epigenomic controller platform to other indications, including inflammatory diseases and fibrosis. These candidates remain earlier in development and have not yet reached pivotal trials in major disease areas. Recent SEC filing outlining Omega Therapeutics pipeline

The company has stated that its approach aims to achieve durable modulation of gene expression through programmable epigenomic controllers while avoiding genome editing. This strategy places Omega Therapeutics in a competitive field with other RNA and gene regulation-focused biotechs such as Alnylam Pharmaceuticals and Beam Therapeutics, which also pursue novel mechanisms to address serious diseases.

How Omega aims to earn money

Omega Therapeutics seeks to generate future revenue primarily through successful development and commercialization of its epigenomic controller-based drug candidates, either independently or with partners. At this stage, the company mainly reports operating losses funded by equity capital and collaboration income rather than product sales.

Where the stock trades today

Omega Therapeutics stock is listed on the Nasdaq in New York under the ticker OMGA, with the most recent tradable quote available in U.S. dollars on that venue.

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.